AU Patent

AU2014312215B2 — Site-specific antibody conjugation methods and compositions

Assigned to AbbVie Stemcentrx LLC · Expires 2020-02-27 · 6y expired

What this patent protects

Provided are antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders. In some aspects, the disclosure provides engineered antibodies that immunospecifically react with a determinant on tumor initiating cells, such as DLL3, SEZ6, or CD324. …

USPTO Abstract

Provided are antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders. In some aspects, the disclosure provides engineered antibodies that immunospecifically react with a determinant on tumor initiating cells, such as DLL3, SEZ6, or CD324. The antibodies comprising one or more unpaired cysteine residues provide site(s) for the selective and controlled conjugation to a therapeutic or diagnostic agent.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014312215B2
Jurisdiction
AU
Classification
—
Expires
2020-02-27
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Stemcentrx LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.